Creative Biolabs is a full-service provider of pharmacological research with general and safety pharmacological experience. Our scientists have extensive experience in the manufacture of vaccine product of the pharmaceutical and CRO industries, so we understand your business needs and your scientific and technical issues.
As an extension of the customer laboratories, we provide our customers with the flexibility of a flexible experimental plan and progress reports for each phase. We offer customized solutions to clients at any stage of the vaccine therapy development process to ensure that the needs of clinical research and therapeutic use are met.
Creative Biolabs adheres to the research requirements of Good Laboratory Practice (GLP) for the safety and efficacy of vaccine engineering process. Our GLP quality control system is widely used in non-clinical research to ensure consistency, reliability, repeatability, quality, and integrity of cancer vaccine safety and efficacy testing.
Creative Biolabs’ biologics process development team can develop the entire process or optimize individual steps in the previous process to ensure that the test studies meet GLP requirements. Upstream, the process development team can screen a variety of production strains to select cell lines that best express the drug. We can optimize processes such as high cell density fermentation to increase product yield and produce the highest quality products in the most efficient and cost-effective manner. For early process development, our biologics team works in tandem with the protein analysis team to ensure product integrity during the early development process.
Based on our expertise in modern omics analytical techniques and precise molecular manipulation tools, our professional team continues to develop innovative, rigorous and powerful tools to provide comprehensive solutions for the pharmaceutical and biopharmaceutical industries for better development of optimized and mass-produced therapeutic vaccine products.
Combining our cell banking, antibody & protein, and vaccine engineering services, we provide GLP/cGMP-compliant cell bank to ensure our customers have access to inexhaustible phenotypically consistent cells.
According to document ICH Q5D ‘Quality of Biological Products: Derivatives and Characterization of Cellular Substrates for the Production of Biotechnology/Biological Products’, Creative Biolabs performs cell bank characterization on the following cell lines:
Please feel free to contact us for more detailed information.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE